Clinical Trial Update: Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 [Phase 2]

View source ↗

Summary

Phase II trial assessing safety and activity of low-dose Interleukin-2 in amyotrophic lateral sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nīmes | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED